Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2010) M. Dreyling et al.   ANNALS OF ONCOLOGY

Erratum: Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence

(2010) Stefan Faderl et al.   CANCER

Galiximab: a review

(2010) Seema Bhat et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Prognostic Factors in Follicular Lymphoma

(2010) Thomas Relander et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98

(2010) Giovanni Martinelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

(2010) Gilles Salles et al.   LANCET

A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy

(2009) R. M. Sharkey et al.   BLOOD

Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

(2009) Thomas E. Witzig et al.   JOURNAL OF CLINICAL ONCOLOGY

Follicular Lymphoma in the United States: First Report of the National LymphoCare Study

(2009) Jonathan W. Friedberg et al.   JOURNAL OF CLINICAL ONCOLOGY

First-line treatment of follicular lymphoma–a patient-oriented algorithm

(2009) Kristin Feuerlein et al.   LEUKEMIA & LYMPHOMA

Follicular lymphoma: maintenance therapy is (often) indicated

(2009) John F. Seymour   Nature Reviews Clinical Oncology

Durable complete responses from therapy with combined epratuzumab and rituximab

(2008) John P. Leonard et al.   CANCER

High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma

(2008) S. Montoto et al.   HAEMATOLOGICA

Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma

(2008) Franck Morschhauser et al.   JOURNAL OF CLINICAL ONCOLOGY